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Abstract
Bone marrow (BM) is the preferred graft source for hematopoietic stem cell transplantation 
(HSCT) in severe aplastic anemia (SAA) compared to mobilized peripheral blood stem cells 
(PBSC). We hypothesized that this recommendation may not apply to those regions where patients 
present later in their disease course, with heavier transfusion load and with higher graft failure 
rates. Patients with SAA who received HSCT from an HLA-matched sibling donor from 1995 to 
2009 and reported to the Center for International Blood and Marrow Transplant Research or the 
Japan Society for Hematopoietic Cell Transplantation were analyzed. The study population was 
categorized by gross national income per capita (GNI) and region/countries into four groups. 
Groups analyzed were high income countries (HIC), which were further divided into US-Canada 
(N=486) and other HIC (N=1264), upper middle-income (UMIC) (N=482), and combined lower 
middle, low income countries (LM-LIC) (N=142). In multivariate analysis, overall survival (OS) 
was highest with BM as graft source in HIC compared to PBSC in all countries or BM in UMIC or 
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LM-LIC (p<0.001). There was no significant difference in OS between BM and PBSC in UMIC 
(p=0.32) or LM-LIC (p=0.23). In LM-LIC the 28-day neutrophil engraftment was higher with 
PBSC compared to BM (97% vs. 77%, p<0.001). Chronic GVHD was significantly higher with 
PBSC in all groups. Whereas BM should definitely be the preferred graft source for HLA-matched 
sibling HSCT in SAA, PBSC may be an acceptable alternative in countries with limited resources 
when treating patients at high risk of graft failure and infective complications.
Introduction
A combined Center for International Blood and Marrow Transplant Research (CIBMTR) 
and European Group for Blood and Marrow Transplantation (EBMT) report on the outcome 
of 692 HLA-matched sibling transplants for severe aplastic anemia (SAA) performed from 
1995 to 2003, concluded that use of peripheral blood stem cells (PBSC) resulted in a worse 
outcome and more chronic graft-versus-host disease (GVHD) in patients younger than 20 
years.1 Another study from the CIBMTR compared different stem cell sources in sibling 
hematopoietic stem cell transplantation (HSCT) for SAA and reached a similar conclusion.2 
A more recent study from EBMT analyzed 1886 patients with SAA who received a first 
sibling HSCT between 1999 and 2009 and showed a survival advantage of BM over PBSC 
in all age groups.3 In the unrelated transplant setting too, mortality was higher in the PBSC 
stem cell recipients as compared to BM transplants.4 The general consensus based on these 
studies is that there is no benefit of PBSC over BM in reducing graft rejection, but there is 
an added adverse consequence of an increased GVHD, and hence there is no compelling 
reason to use PBSC for transplants in SAA.
Despite these recommendations, literature from developing countries suggests that PBSC is 
more frequently used than BM.5-9 The rationale being given is that there is a higher risk of 
graft failure and mortality when BM is used, although this is at variance with the large 
published registry data. As the majority of HSCT are performed in countries with advanced 
health facilities, any analysis of pooled data from international registries may predominantly 
reflect the outcome in more affluent countries. To assess if there were differences in 
outcome in different economic regions using the two graft sources, we analyzed 2374 
patients of SAA transplanted from 1995 to 2009, according to the economic regions where 
the transplants were performed.
Methods
This is a retrospective study of patients who had undergone their first HSCT from an HLA-
matched sibling for SAA from 1995 to 2009 and reported to the CIBMTR or the Japan 
Society for Hematopoietic Cell Transplantation (JSHCT). The Center for International 
Blood and Marrow Transplant Research (CIBMTR) database is a voluntary research 
affiliation of more than 450 transplantation centers worldwide that contribute detailed data 
on all completed autologous and allogeneic hematopoietic cell transplantation (HCT) to a 
Statistical Center at the Medical College of Wisconsin in Milwaukee. Observational studies 
conducted by the CIBMTR are performed in compliance with the Health Insurance 
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Portability and Accountability Act (HIPAA) as a Public Health Authority, as well as all 
applicable federal regulations pertaining to the protection of human research participants.
The Japan Society for Hematopoietic Cell transplantation (JSHCT) collects HCT recipient 
clinical data in collaboration with Japan Society for Pediatric Hematology and Oncology, 
Japan Marrow Donor Program and cord blood banks in Japan by using the Transplant 
Registry Unified Management Program (TRUMP), as described previously.10 This study 
was approved by the data management committee of the JSHCT, and by the institutional 
review board of National Defense Medical College.
The data were analyzed according to the World Bank Economic classification, based on the 
gross national income (GNI) per capita and according to the country and region. As per the 
GNI, countries were divided into: high-income countries (HIC), upper middle-income 
countries (UMIC), lower middle-income countries (LMIC) and low-income countries (LIC). 
The HIC were divided into USA-Canada (US-C) and other HIC (OHIC), due to the greater 
representativeness of country data from US-C. The LMIC and LIC were combined into 
lower middle, low-income countries (LM-LIC) due to small numbers from each.11
The outcome measures were (a) Overall survival (OS): time to death from any cause with 
patients censored at last follow-up, (b) Neutrophil engraftment: achievement of absolute 
neutrophil count (ANC) ≥ 0.5 × 109/L for 3 consecutive days; this was used as a marker of 
primary engraftment, (d) Acute GVHD, coded as present if grade 2 or greater, based on the 
Glucksberg grading system, (e) Chronic GVHD, including both limited and extensive 
disease.
Statistical Analysis
The probabilities of overall survival were calculated using the Kaplan-Meier method. Death 
from any cause was considered as an event and surviving patients were censored at last 
follow-up. Log-rank p-values were calculated to evaluate the overall differences of the 
survival rates between BM and PBSC. The probabilities of all other outcomes were 
estimated using the crude cumulative incidence function to account for competing risks 
(death without the event). The Gray's test p-values were calculated to evaluate the overall 
differences across the cumulative incidence functions. 95% confidence intervals (CI) were 
calculated using arcsine- square root transformation. Cox proportional hazards regression 
models were constructed with economic status classification and graft source as main 
effects. The proportional hazards assumption was tested. The covariates included in the 
analysis were the main effect, age, ATG/alemtuzumab, donor-recipient CMV status prior to 
the transplantation, time from diagnosis to transplantation, Karnofsky performance score 
(KPS) at the time of transplantation, conditioning regimen, GVHD prophylaxis, sex, prior 
therapy, and year of transplantation. Significant covariates were selected using backward 
elimination. Logistic regression was used for neutrophil recovery. A binary outcome variable 
was created based on neutrophil recovery status at day 28. The interactions between the 
main effect and significant covariates were also examined. All analyses were performed with 
SAS (SAS Institute Inc.). Having a p-value of less than 0.05 was considered statistically 
significant.
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Results
Patient Characteristics
During the period 1995 to 2009, 2374 HLA identical sibling transplants for aplastic anemia 
were reported to CIBMTR (N=1814) and JSHCT (N=560). Bone marrow was used as a stem 
cell source in 1927 patients and PBSC in 447. Most of the transplants were from high 
income countries, with US-C having 486, OHIC: 1264, UMIC: 482 and LM-LIC reporting 
only 142 (Table 1). There were marked differences in number of transplants reported from 
different WHO regions, with Africa reporting 29, Americas: 896, Eastern Mediterranean: 
236, Europe: 278, South East Asia: 35 and Western Pacific: 900 (country and WHO data 
shown in supplementary Table S1).
More males underwent transplant compared to females. The gender difference was highest 
in the LM-LIC and least in the higher income countries. Age at transplant was higher in 
PBSC compared to BM in all economic zones. Performance status was lower in PBSC 
recipients compared to BM, except in LM-LIC. Time to transplant was longer in PBSC 
group compared to BM recipients, except in LM-LIC. Prior therapy with ATG was given to 
a higher proportion of patients in high income countries (23%) compared to UMIC (5%) and 
LM-LIC (8%). Androgen as prior therapy was used in about 23% cases in LM-LIC, with 
lower percent in UMIC (11%) and very few in high income countries. Cyclophosphamide 
(Cy) and ATG (Cy-ATG) was the most common conditioning regimen, followed by Cy 
without ATG.
Overall Survival
On univariate analysis, the 1-yr and 5-yr OS was significantly better with BM compared to 
PBSC in high- income countries (p<0.001 at both 1-yr and 5-yr for US-C; p=0.006 at 1-yr, 
and p=0.001 at 5-yr for other HIC) (Table 2). In UMIC at 1 and 5 years, there was a non-
significant trend for better survival with BM as a graft source compared to PBSC (1-year: 
76% vs. 67%, p=0.13; 5-year: 69% vs. 57%, p=0.15, respectively). In LM-LIC, there was 
also a non-significant trend for worse survival with BM compared to PBSC (1-year: 56% 
(95% CI, 39-73%) vs. 72% (61-81%), p=0.14; 5-year: 46% (27-65%) vs. 61% (49-73%), 
p=0.19).
On multivariate analysis, as compared to BM in US-C, the OS with BM was not 
significantly different in other HIC (relative risk (RR) 1.1, p=0.71), and was inferior with 
BM in UMIC (RR 2.5, p<0.0001) and LMIC (RR 5.4, p<0.0001); it was also inferior with 
PBSC as a graft source in US-C, other HIC, UMIC, LM-LIC (RR 2.9, p<0.0001; RR 1.5, 
p=0.02; RR 3.1, p<0.0001; RR 3.7, p<0.0001 respectively) (Table 3). Comparing BM as a 
graft source between UMIC and LM-LIC, the OS was superior in UMIC (RR 0.47, 
p=0.002). Comparing BM and PBSC within the same GNI group, OS was not significantly 
different between BM and PBSC in either UMIC (RR 0.8, p=0.33) or LM-LMIC (RR1.4, 
p=0.23) (Fig 1a, b, c, d).
Age at transplant had a significant effect on OS, with age at transplant < 20 years showing 
better OS compared to ages 20-39 or ≥ 40 years (RR 1.7, p<0.0001; RR 3.97, p<0.0001). A 
better performance status (KPS 90% or more) showing significantly better OS compared to 
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poorer performance (RR 1.4, p=0.0003). The year of transplant had an influence on OS. As 
compared to transplants performed in the years 1995-1997, OS was better in transplants 
performed in the years 1998-2000, 2001-2003, 2004-2006 and 2007-2009 (RR 0.77, p=0.04; 
RR 0.6, p=0.0009; RR 0.5, p<0.0001; RR 0.4, p<0.0001),(Table 3). The effect of the 
conditioning regimen and GVHD prophylaxis on survival was analyzed, and there was no 
significant effect of these on OS (data not shown).
Neutrophil Engraftment
On univariate analysis, there was no significant difference in the 28-day neutrophil 
engraftment between the BM and PBSC groups in US-C (85% (95% CI, 81-88) vs. 89% 
(81-95), p=0.31) or other HIC (91% (89-92) vs. 93% (90-9%), p=0.14). There was a 
significantly lower 28-day neutrophil engraftment in the BM group compared to the PBSC 
group in UMIC (75% (95% CI, 71-79) vs. 90% (82-96), p<0.001) and LMIC (77% (64-88) 
vs. 97% (92-99), p=0.002) (Table 2).
On multivariate analysis for the 28-day neutrophil engraftment comparing groups within the 
same economic zones, there was no significant difference in neutrophil engraftment between 
BM and PBSC recipients within US-C (p=0.12) or other HIC (p=0.33), respectively (Table 
4). In contrast, there was a significantly lower neutrophil engraftment in BM recipients 
compared to PBSC in UMIC (odds ratio [OR] 0.20 (95% CI, 0.047 - 0.844), p = 0.028) and 
LM-LIC (OR 0.057 (0.006 – 0.47), p=0.008) for the day 28 neutrophil engraftment. 
Comparing different economic zones, neutrophil recovery in BM recipients in US-C was 
lower compared to BM or PBSC recipients in OHIC (data not shown). The neutrophil 
engraftment as per different economic classification is shown in Figure 2.
The primary graft failures in US-C, other HIC, UMIC and LM-LIC with BM were 2%, 4%, 
11% and 19% while with PBSC were 10%, 4%, 8% and 2% respectively. Secondary graft 
failure rates in US-C, other HIC, UMIC and LM-LIC with BM were 3%, 3%, 6% and 6% 
while with PBSC were 4%, 2%, 2% and 5% respectively.
Graft versus host disease
On univariate analysis, acute GVHD (grade 2-4) was higher with PBSC compared to BM in 
US-C and LM-LIC (at 100-day, US-C: 20% (95% CI, 12-30) vs. 11% (8-14), p=0.05; LM-
LIC: 39% (30-49) vs. 23% (12-36), p=0.04, respectively); there was no significant difference 
in other HIC and UMIC (at 100-day, other HIC: 16% (95% CI, 10-23) vs. 10% (8-13), 
p=0.11; UMIC: 10% (4-18) vs. 10% (7-13), p=0.96, respectively). Grade 3-4 acute GVHD 
was not different at day 100 between the two graft sources. Chronic GVHD at 1 and 5 years 
was higher with PBSC compared to BM in US-C (at 1-year, 31% (95% CI, 21-42) vs. 17% 
(14-21), p=0.02; at 5-year, 39% (29-51) vs. 22% (18-26), p=0.003); other HIC (at 1-year, 
20% (14-26) vs. 11% (9-13), p=0.005; at 5-year, 25% (13-31) vs. 13% (11-16), p <0.001); 
UMIC, (at 1-year 28% (17-41) vs. 13% (10-17), p=0.02; at 5-year 28% (17-41) vs. 16% 
(13-20), p=0.07); and LM-LIC (at 1-year 43% (31-56) vs. 9% (2-22), p<0.001; at 5-year 
53% (40-66) vs. 9% (2-22) p<0.001), shown in Table 2.
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Cause of Death
The various causes of death are shown in Table 5. In the combined high income countries, 
there were few deaths due to graft failure (1.2%) or infections (2.9%) using BM as a graft 
source. In contrast, there were higher deaths due to graft failure and infections using BM as 
a graft source in UMIC (4.5% and 11.2% respectively) and LM-LIC (14.6% and 12.5% 
respectively). When PBSC was used as a graft source, there were more deaths due to graft 
failure and infections in US-C (8.7% and 12.5% respectively) compared to other HIC (1.4% 
and 8.6% respectively). Deaths attributed to graft failure were lower with PBSC as a graft 
source compared to BM in UMIC (0% vs. 4.5%, respectively) and in LM-LIC (5.3% vs. 
14.6%, respectively). Deaths due to infections were lower with PBSC (7.4%) compared to 
BM (12.5%) in LM-LIC. Causes of death as reported to the registries have inherent 
limitations, as death is often caused by multiple factors.
Economic Regions
The regions classified as LM-LIC were mainly located in Asia and the Middle-East. A color 
figure of the map of the world, showing how the regions were divided according to their 
GNI is attached. (Figure 3)
Discussion
Registry based studies have the advantage of providing large, pooled, real-world data to 
answer clinical questions. For complex and expensive therapies like HSCT, the data would 
mainly be generated by centers in affluent countries, with potential for limited 
generalizability in less affluent countries. Our study shows that 73.7% transplants were from 
the high income countries, 20.3% from upper middle income countries and only 6% percent 
from the LM-LIC. The increased number of transplants in the more affluent countries is 
expected, as the HSCT rates are closely linked with gross national income per capita. 12 The 
incidence of aplastic anemia is estimated to be around 2 per million in the western 
world, 13-16 and is likely two to three times higher in Asia 17,18 with relatively larger number 
of aplastic anemia patients admitted to hospitals in Asia relative to Europe and US.19 The 
recent analyses on HSCT in SAA have not looked for any differences in outcomes from the 
less economically developed regions.1-3 If there are any differences in transplant practices 
and outcomes in the UM or LM-LIC these are likely to be missed in pooled registry 
analysis. This study was conducted to determine if any such differences exist.
Our results show that the outcomes of transplant were better in high income countries 
compared to UMIC and LM-LIC. The OS with BM as a graft source in US-Canada and 
other HIC was better than with PBSC. This finding is similar to that reported in previous 
studies.1,2,20 However, in UMIC and LM-LIC, there were no significant differences in OS 
between BM and PBSC. The likely reasons for these differences may be inferred by the 
differences in neutrophil engraftment, GVHD and causes of death.
There were lower neutrophil engraftment rates with BM compared to PBSC in LM-LIC and 
UMIC. These findings are at variance with the study by Bacigalupo et al. who did not 
observe any difference in engraftment between the two graft sources.3 Even in our study, 
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there was no difference in the combined HIC (US-Canada and OHIC) and if we had not 
analyzed as per GNI, we would not have detected these differences. There were higher 
deaths due to graft failure and infections in BM recipients compared to PBSC, in UMIC and 
LM-LIC. Chronic GVHD was higher in all economic zones with PBSC, as expected.
The retrospective nature of our study does not allow us to offer explanations for all the 
observed differences. There are also limitations of low numbers from LM and LIC and even 
the HIC and UMIC are not uniformly represented. These constraints are inherent in any 
registry data, as international participation is influenced by local resources as well as choice 
of other registries. Nevertheless, this analysis has the largest number of cases compared to 
recent registry studies on aplastic anemia.1-4 A review of literature may allow us to make 
logical inferences. The superior outcome in HIC compared to UMIC and LM-LIC is 
expected as health outcomes correlate with economic development. The World Health 
Statistics 2014 report shows that even in 2012, life expectancy and mortality rates in LM-
LIC were inferior to those seen in HIC in 1990. While the rates in UMIC are also inferior to 
HIC, the differences are less marked.21 These indicators suggest that in developing 
countries, socioeconomic factors, along with health care infrastructure, lag behind the 
economically advanced countries by many years.
Hence the past experiences of high income countries may be relevant to the present 
transplant outcomes in the less economically advanced countries. In the 1970s the outcomes 
of transplant for SAA in HIC were inferior to current results, since graft rejection rates 
varied from 30% to 70% in multiply transfused patients and mortality was high in them.22-26 
Over time, survival increased significantly to levels as high as 90% in the 1990s.27,28
A major cause of graft rejection is transfusion associated sensitization to minor 
histocompatibility antigens due to prior blood transfusions.29,30 Comparison of transplants 
between transfused versus untransfused patients confirmed the finding of lower graft 
rejection and higher survival in untransfused patients.31,32 A cell marrow dose of < 3 × 108 
cells/ kg was also associated with graft rejection.27,33,34 A number of factors led to 
improved outcomes, such as a decrease in time from diagnosis to HSCT, transplants in 
untransfused patients, use of leucodepleted blood, universal leucodepletion in many 
countries, improvement in conditioning and better immunosuppression for GVHD.27,32,35-37
Our study shows that in UM and LM-LIC, the OS was not significantly different with BM 
compared to PBSC despite having a higher chronic GVHD. The rate of neutrophil recovery 
with PBSC in UM and-LM-LIC was significantly faster compared to BM. Deaths due to 
graft failure and infections were higher with BM recipients compared to PBSC group in 
LM-LIC as well as UMIC. This suggests that the benefits of earlier and reliable engraftment 
compensated for the complications of higher GVHD with PBSC.
We do not have data about the number of blood transfusions pre-HSCT and whether the 
blood products were leucodepleted, irradiated or CMV selected. Studies from less 
economically developed countries suggest that because of delays in HSCT, patients in these 
countries are multitransfused with high risk of graft rejection and may be infected with high 
risk of graft rejection and may be infected at the time of HSCT.7,8,38,39 Patients are also at 
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higher risk due to CMV positivity present in almost 100% donors and recipients in many of 
these countries.39-41 Leucodepletion of blood is uncommon in LIC.6,35,42-44
In transplant literature, cost of transplant is not recognized as a risk factor for poor outcome, 
as most HIC have state or insurance funded health care. But in LM-LIC, and some UMIC, 
the cost of HSCT is a special concern, as majority of patients pay out of pocket.45,46 
Funding is through sponsorship by government, non-governmental organizations (NGOs) 
and charitable organizations.6,7,38,40,44 Delay in engraftment or in resolution of infections 
would lead to exhaustion of funds for further treatment leading to fatality. Hence, unlike in 
HIC where patients can be supported for long periods of time, limited funds compel 
transplant programs for the fastest engraftment and independence from blood component 
transfusions as well as control of infections. Most centers use G-CSF to hasten neutrophil 
recovery.7,8 The adverse consequence of PBSC use would be a greater risk of chronic 
GVHD and hence a higher cost of treating this complication. For patients paying out of 
pocket, managing costs of chronic GVHD spread over time may be easier than arranging 
immediate finances for a complicated transplant admission.
It is also known that graft failure may be reduced or salvaged by increasing the number of 
stem cells infused, and supplementation with PBSCs.47,48 PBSCs offer advantages in terms 
of earlier neutrophilic engraftment, and shorter hospitalization, issues which are relevant in 
these countries. Hence in many developing countries, PBSC is used as the predominant or 
sole graft source in SAA.5,6,40,49-51 Survival rates in this high risk population, with PBSC 
are reported as 75-80%.40,43,49,51
Our data also showed that in LM-LIC there were lower numbers of females compared to the 
HIC groups, possibly representative of social factors. Additionally, there was poorer 
performance status, higher CMV prevalence (data not shown), delay in HSCT (from 
diagnosis >3 months) and lower use of prior ATG therapy. These factors are likely indicators 
of poor socio-economic factors and limitations in health resources. In UMIC there was a 
lower use of ATG in conditioning compared to HIC which may explain the lower survival 
compared to BM grafts in high income countries. In US-Canada, the results of PBSC 
transplants were inferior compared to PBSC in other HIC, for reasons that are not clear. It is 
possible that in US-Canada, PBSC grafts were used in patients with pre-existing 
complications in order to achieve early engraftment, and the higher mortality was partly a 
reflection of the underlying co-morbidities. Despite the limitations of numbers from certain 
countries, the differences in survival based on economic regions are provocative.
Conclusions
The major findings of our study confirm the general recommendation that the best outcomes 
of HSCT in SAA are with BM as a graft source.1-3 However, as there was no significant 
survival difference between the two graft sources in UMIC and LM-LIC, PBSC may also be 
an acceptable graft source in countries with resource constraints when dealing with high risk 
SAA patients. This should be a decision based on the assessment of risk of graft failure, 
earlier neutrophil recovery and shorter hospitalization versus a higher risk of chronic GVHD 
with its attendant long term consequences. Our study also demonstrates that pooled analysis 
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from registry data may miss important differences in transplant practices and outcomes in 
different parts of the world. Since any combined registry study dealing with expensive 
therapies would mainly reflect the outcomes of HIC, recommendations based on such 
studies should cater for variations in different economic zones to make them more relevant 
to the population there.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Overall survival was better with bone marrow as graft source in sibling 
transplants for aplastic anemia.
• Chronic graft-versus-host disease was worse with peripheral blood stem cells as 
graft source.
• In non-high-income countries, there was no significant survival difference 
between the two graft sources.
• Analysis of registry data should cater for variations in outcomes in different 
economic regions.
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Figure 1. Overall survival curves after HSCT, comparing BM vs. PBSC as graft sources
(A) In US-Canada. (B) In other HIC. (C) In UMIC. (D) In LM-LIC.
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Figure 2. Cumulative incidence for neutrophil engraftment comparing BM vs. PBSC as graft 
sources
(A) In US-Canada. (B) In other HIC. (C) In UMIC. (D) In LM-LIC.
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Figure 3. Map of the world showing regions classified according to their GNI
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Table 2
Results of univariate analysis: overall survival, neutrophil engraftment and GVHD
BM (No. = 1927)
Probability percent (95% CI)
PBSC (No. =447)
Probability percent (95% CI) p
Overall Survival
 US-Canada 1-year 92 (89-94) 66 (55-76) <0.001
5-year 88 (84-91) 56 (45-67) <0.001
 Other HIC 1-year 90 (88-92) 82 (77-87) 0.006
5-year 87 (85-89) 77 (70-82) 0.001
 UMIC 1-year 76 (72-80) 67 (54-78) 0.13
5-year 69 (64-73) 57 (43-72) 0.15
 LM-LIC 1-year 56 (39-73) 72 (61-81) 0.14
5-year 46 (27-65) 61 (49-73) 0.19
Neutrophil Engraftment
 US-Canada 28-day 85 (81-88) 89 (81-95) 0.31
100-day 98 (96-99) 91 (84-96) 0.04
 Other HIC 28-day 91 (89-92) 93 (90-96) 0.14
100-day 96 (95-97) 96 (94-99) 0.83
 UMIC 28-day 75 (71-79) 90 (82-96) <0.001
100-day 91 (88-93) 92 (84-97) 0.70
 LM-LIC 28-day 77 (64-88) 97 (92-99) 0.002
100-day 82 (70-91) 98 (94-100) 0.006
Grade 2-4 Ac GVHD at 100 day
 US-Canada 11 (8-14) 20 (12-30) 0.05
 Other HIC 10 (8-13) 16 (10-23) 0.11
 UMIC 10 (7-13) 10 (4-18) 0.96
 LM-LIC 23 (12-36) 39 (30-49) 0.04
Grade 3-4 Ac GVHD at 100 day
 US-Canada 5 (3-8) 11 (5-19) 0.10
 Other HIC 6 (4-8) 11 (6-16) 0.12
 UMIC 7 (5-10) 6 (2-14) 0.77
 LM-LIC 8 (2-18) 16 (9-24) 0.17
Chronic GVHD
 US-Canada 1-year 17 (14-21) 31 (21-42) 0.02
5-year 22 (18-26) 39 (29-51) 0.003
 Other HIC 1-year 11 (9-13) 20 (14-26) 0.005
5-year 13 (11-16) 25 (19-31) <0.001
 UMIC 1-year 13 (10-17) 28 (17-41) 0.02
5-year 16 (13-20) 28 (17-41) 0.07
 LM-LIC 1-year 9 (2-22) 43 (31-56) <0.001
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BM (No. = 1927)
Probability percent (95% CI)
PBSC (No. =447)
Probability percent (95% CI) p
5-year 9 (2-22) 53 (40-66) <0.001
Abbreviations are explained in Table 1.
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Table 3
Results of multivariate analysis: overall survival
Variable Relative Risk (95% CI) p
Countries by GNI, Graft Source (No.)
US-Canada, BM* (406) 1
Other HIC, BM (1051) 1.062 (0.773-1.459) 0.7112
UMIC, BM (418) 2.521 (1.829-3.475) <0.0001
LM-LIC, BM (48) 5.367 (3.126-9.216) <0.0001
US-Canada, PBSC (80) 2.892 (1.881-4.448) <0.0001
Other HIC, PBSC (209) 1.554 (1.052-2.295) 0.0266
UMIC, PBSC (64) 3.16 (1.919-5.204) <0.0001
LM-LIC, PBSC (94) 3.695 (2.291-5.959) <0.0001
 CONTRAST
Other HIC BM vs. UMIC BM 0.4212 (0.3265-0.5432) <0.0001
Other HIC BM vs. LM-LIC BM 0.1978 (0.1193-0.3281) <0.0001
UMIC BM vs. LM-LIC BM 0.4697 (0.2854-0.773) 0.0029
UMIC BM vs. UMIC PBSC 0.7978 (0.5071-1.255) 0.3284
LM-LIC BM vs. LM-LIC PBSC 1.4528 (0.7881-2.6782) 0.2314
US-C PBSC vs. UMIC PBSC 0.9152 (0.5356-1.5639) 0.7459
US-C PBSC vs. LM-LIC PBSC 0.7829 (0.4655-1.3166) 0.3561
Age in years (No.)
< 20* (1169) 1
20-39 (909) 1.694 (1.371-2.093) <0.0001
≥ 40 (292) 3.976 (3.053-5.179) <0.0001
KPS (No.)
≥ 90%* (1302) 1
<90% (812) 1.422 (1.174-1.721) 0.0003
Missing (256) 0.895 (0.609-1.316) 0.5737
Year of transplant (No.)
1995-1997* (598) 1
1998-2000 (510) 0.772 (0.605-0.986) 0.0379
2001-2003 (468) 0.638 (0.489-0.833) 0.0009
2004-2006 (490) 0.553 (0.415-0.738) <0.0001
2007-2009 (304) 0.434 (0.293-0.641) <0.0001
GNI indicates gross national income; other abbreviations explained in Table1;
*indicates reference category.
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kumar et al. Page 21
Table 4
Results of multivariate analysis: neutrophil engraftment on day 28
Variable Countries by GNI, Graft Source (No.) Odds Ratio (95% CI) p
US-Canada, BM* (397) 1
Other HIC, BM (927) 2.15 (1.3891-3.3277) 0.0006
UMIC, BM (387) 0.5981 (0.391-0.9149) 0.0178
LM-LIC, BM (45) 0.5746 (0.2495-1.323) 0.1929
US-Canada, PBSC (73) 3.1664 (0.7406-13.5376) 0.12
Other HIC, PBSC (193) 3.4151 (1.3122-8.8878) 0.0118
UMIC, PBSC (59) 2.9857 (0.7002-12.7307) 0.1393
LM-LIC, PBSC (92) 10.0537 (1.3613-74.2476) 0.0237
 CONTRAST
Other HIC BM vs. UMIC BM 3.5948 (2.4069-5.3689) <0.0001
Other HIC BM vs. LM-LIC BM 3.742 (1.6434-8.5207) 0.0017
Other HIC BM vs. Other HIC PB SC 0.6296 (0.2444-1.6218) 0.3378
UMIC BM vs. UMIC PBSC 0.2003 (0.0475-0.8448) 0.0286
LM-LIC BM vs. LM-LIC PBSC 0.05715 (0.006884-0.4744) 0.008
Abbreviations explained in Table 1 and 3.
*indicates reference category.
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